IMRX stock news · Immuneering Corporation
Get alerts for IMRX
Follow Immuneering Corporation (IMRX) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for IMRXFree on the App Store and Google Play, or on the web.
Andrew Gengos, CFO of Immuneering Corporation, bought $90,000 worth of company stock.
Good for IMRXImmuneering's chief financial officer Andrew Gengos bought $90,000 of shares at $3.58 each. It is a modest positive sign of leadership confidence, not proof of better results.
Immuneering showed new research on how atebimetinib could work well with other treatments for pancreatic cancer.
Good for IMRXImmuneering reported promising early results for atebimetinib combinations, including in a pancreatic cancer model. This supports its treatment program, but does not show whether the drug works in people.